Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical ...

The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular ...

Primary aldosteronism has been recognized as a common cause of secondary hypertension, accounting for approximately 10% of the hypertensive population. Screening should be applied in hypertensive ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease ...

Cortisol mobilizes sugar for you while insulin stores sugar. When you don’t have enough of it, you end up with low sugar and, ...

Increasing recognition of the role of aldosterone in cardiovascular disease has been supported by a significant body of evidence from animal models. This evidence has been translated into clinical ...

The cardiology landscape is rapidly evolving. Novel risk factors and new tools are reshaping CV risk assessment and ...

A new study from researchers at Brigham and Women’s Hospital suggests that a hormone called aldosterone may play a much ...

The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the ...

Grinspoon noted that even incremental reductions in blood pressure incidence can translate into meaningful declines in cardiovascular events at the population level. In people living with HIV, who ...

Skipping water in the morning can gradually increase blood pressure over time. Before grabbing a cup of coffee, have a glass ...

Guideline-directed medical therapy and dose titration are essential to improving outcomes in heart failure with reduced or ...